Lexeo Therapeutics, Inc. (LXEO) stock
LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.96+0.01 (+0.34%)
Close on Nov 20, 2026Market cap $242.86MP/E –Yield –
Lexeo Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Lexeo Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$88.70M. For fiscal 2025 it was -$98.96M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$98.96M | – |
| FY2024 | Dec 31, 2024 | -$81.63M | – |
| FY2023 | Dec 31, 2023 | -$59.61M | – |
| FY2022 | Dec 31, 2022 | -$55.23M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.18M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.84M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.33M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.65M | – |
See a number that looks wrong?